Gelesis Holdings Inc (GLS) stock has risen 9.73% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.
Gelesis Holdings Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GLS!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With GLS Stock Today?
Gelesis Holdings Inc (GLS) stock is trading at $4.85 as of 2:17 PM on Wednesday, Apr 27, a rise of $0.41, or 9.23% from the previous closing price of $4.44. The stock has traded between $4.40 and $5.25 so far today. Volume today is light. So far 71,360 shares have traded compared to average volume of 181,732 shares.
To screen for more stocks like Gelesis Holdings Inc click here.
More About Gelesis Holdings Inc
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Click Here to get the full Stock Report for Gelesis Holdings Inc stock.